- Home
- OTLK vs PEPG Comparison
OTLK vs PEPG Comparison
Compare OTLK & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- PEPG
- Stock Information
- Founded
- OTLK 2010
- PEPG 2018
- Country
- OTLK United States
- PEPG United States
- Employees
- OTLK N/A
- PEPG N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- OTLK Health Care
- PEPG Health Care
- Exchange
- OTLK Nasdaq
- PEPG Nasdaq
- Market Cap
- OTLK 48.3M
- PEPG 45.5M
- IPO Year
- OTLK 2016
- PEPG 2022
- Fundamental
- Price
- OTLK $2.25
- PEPG $1.35
- Analyst Decision
- OTLK Strong Buy
- PEPG Buy
- Analyst Count
- OTLK 5
- PEPG 3
- Target Price
- OTLK $9.60
- PEPG $7.67
- AVG Volume (30 Days)
- OTLK 987.3K
- PEPG 350.6K
- Earning Date
- OTLK 08-13-2025
- PEPG 08-07-2025
- Dividend Yield
- OTLK N/A
- PEPG N/A
- EPS Growth
- OTLK N/A
- PEPG N/A
- EPS
- OTLK 0.83
- PEPG N/A
- Revenue
- OTLK N/A
- PEPG N/A
- Revenue This Year
- OTLK N/A
- PEPG N/A
- Revenue Next Year
- OTLK $419.06
- PEPG N/A
- P/E Ratio
- OTLK $2.62
- PEPG N/A
- Revenue Growth
- OTLK N/A
- PEPG N/A
- 52 Week Low
- OTLK $0.87
- PEPG $0.88
- 52 Week High
- OTLK $9.10
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- OTLK 67.03
- PEPG 53.26
- Support Level
- OTLK $2.16
- PEPG $1.07
- Resistance Level
- OTLK $2.45
- PEPG $1.32
- Average True Range (ATR)
- OTLK 0.16
- PEPG 0.09
- MACD
- OTLK 0.05
- PEPG 0.02
- Stochastic Oscillator
- OTLK 81.01
- PEPG 81.19
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.